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ProtectionAn effective immunological response in the lungs during a pneumococcal infection is a key factor to the
bacteria clearance and prevention of sepsis. In order to develop broad-range pneumococcal vaccines sev-
eral pneumococcal proteins and strong adjuvants have been investigated. Previously, we constructed a
recombinant BCG (rBCG) strain expressing a fragment of PspA (Pneumococcal surface protein A) fused
to PdT (detoxified form of pneumolysin). Immunization of mice with a priming dose of rBCG PspA-PdT
followed by a booster dose of rPspA-PdT fused protein induced a high antibody response in the serum
and protected mice against lethal challenge. Here, we investigated the humoral and cellular immune
response in the Bronchoalveolar lavage fluid (BALF). Immunization of mice with rBCG PspA-PdT /
rPspA-PdT induced rapid clearance of bacteria after challenge, an early control of the cellular influx
and reduced inflammatory cytokine levels in the BALF. In addition, rBCG PspA-PdT / rPspA-PdT induced
higher lymphocyte recruitment to the lungs at 48 h, showing an increased percentage of CD4+ T cells.
Furthermore, BALF samples from mice immunized with rBCG PspA-PdT / PspA-PdT showed high binding
of IgG2c and enhanced complement deposition on the pneumococcal surface; antibody binding was
specific to PspA as no binding was observed to a PspA-knockout strain. Taken together, our results show
that the immunization with rBCG PspA-PdT / rPspA-PdT induces humoral and cellular immune responses
in the lungs, promotes an early clearance of pneumococci and protects against the systemic dissemina-
tion of pneumococci.
 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pneumococcal proteins have been extensively investigated as
alternative pneumococcal vaccines. Whereas polysaccharide-
based vaccines induce protection restricted to the serotypes
included in the vaccine formulation, well-conserved proteins are
able to induce protective responses against pneumococcal strains
bearing different capsular types [1]. The selection of the antigen,
adjuvant and delivery system are key factors to the development
of a successful vaccine. BCG is a live attenuated anti-tuberculosis
vaccine, able to induce both humoral and cellular immuneresponses [2]. Due its adjuvant properties, BCG strains have been
evaluated as delivery system for heterologous antigens derived
from viruses, bacteria and parasites [3].
The Pneumococcal surface protein A (PspA) is highly immuno-
genetic and interferes with complement deposition onto the pneu-
mococcal surface, reducing opsonophagocytosis [4]. Pneumolysin
(Ply) is a cytolysin that plays an important role in the evasion of
the host immune system, forming pores in cholesterol-containing
cell membranes and activating the complement system during
pneumococcal infections [5,6]. Antibodies generated against
recombinant PspA and PdT, a genetically detoxified form of Ply,
are able to inhibit their activity and promote an efficient immuno-
logical response leading to protection against systemic disease
[7,8]. In addition, Langermann and colleagues (1999) demon-
strated that rBCG strains expressing PspA fragments protected
mice against a lethal pneumococcal challenge [9].
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fusion protein composed by PspA and PdT (rPspA-PdT) [10]. In
order to improve the immunogenicity of this protein we con-
structed a rBCG strain to deliver PspA-PdT through a live atten-
uated vector (rBCG PspA-PdT) [11]. Immunization of mice with
the rBCG PspA-PdT as a priming dose and a single dose of
rPspA-PdT as a booster (rBCG PspA-PdT / rPspA-PdT) induced a
high antibody response against both proteins in the sera, pro-
moted a shift from IgG1 to IgG2 antibody isotype and increased
the expression of inflammatory cytokines in splenocytes culture.
Furthermore, immunization with rBCG PspA-PdT / rPspA-PdT
protected mice against pneumococcal aspiration pneumonia/sep-
sis challenge [11].
Since pneumococcal pneumonia usually precedes the invasion
of the bacteria to the bloodstream [12], the immunological
responses induced in the lungs are a key factor to prevent dis-
ease dissemination. In addition, it is known that neutrophils
are quickly recruited to the lungs during a pneumococcal infec-
tion, playing an important role in the bacterial clearance [13].
However, an exacerbated inflammatory response characterized
by prolonged cellular influx and increased release of inflamma-
tory cytokines is correlated with tissue damage and poor prog-
nosis of the pneumococcal disease [13–15]. Immunization of
mice with several pneumococcal antigens including PspA and
pneumolysoids has been shown to promote a more rapid clear-
ance of pneumococci, which results in reduced neutrophil
recruitment and controled cytokine release in the lungs, leading
to protection against tissue damage and increasing the survival
after pneumococcal challenge [8,15,16].
In this context, we investigated the role played by humoral and
cellular immune responses in the Bronchoalveolar lavage fluid
(BALF) induced by subcutaneosly immunization of mice with rBCG
PspA-PdT / rPspA-PdT that leads to rapid pneumococcal clearence
in the first hours after intranasal challenge.2. Material and methods
2.1. Pneumococcal strains
S. pneumoniae strains WU2 (PspA+) and JY119 (PspA-) were
grown as previous described [10] and maintained at 80 C until
used.2.2. Mouse immunization
All animal experiments were approved by the Ethics Committee
at Instituto Butantan, São Paulo – SP (CEUAIB), (Permit Number
1360/15). Female C57BL/6 mice (n = 5 mice per time point for each
group) from Faculdade de Medicina – Universidade de São Paulo
(São Paulo, Brazil) were immunized subcutaneously (s.c.) with
1  106 CFU of rBCG PspA-PdT or WT-BCG; mice of the Control
group received sterile 0.9% saline solution. rPspA-PdT protein
(10 mg) was administered (s.c.) in saline and 100 mg of Al(OH)3 as
adjuvant [11], as a single dose (rPspA-PdT group) or as a booster
dose 30 days after priming with WT-BCG or rBCG PspA-PdT
(WT-BCG / rPspA-PdT and rBCG PspA-PdT / rPspA-PdT groups).2.3. Intranasal pneumococcal challenge
Immunized mice were anesthetized by i.p. injection of a mix-
ture containing ketamine (100 mg/Kg) and xylazine (10 mg/Kg)
21 days after the last dose, before receiving 1  106 CFU of the
WU2 pneumococcal strain in 50 mL saline delivered intranasally
by aspiration.2.4. Blood and Bronchoalveolar lavage fluid (BALF) collection and cell
count
Blood samples from the retro-orbital plexus were collected and
maintained in heparinized tubes. Mice were euthanized by i.p.
injection with a mixture containing ketamine (300 mg/Kg) and
xylazine (30 mg/Kg) before or at the indicated time points after
challenge. For BALF collection, the trachea was cannulated using
a catheter and lungs were rinsed twice with 0.5 and 1.0 mL of cold
PBS and collected samples kept on ice. Cells obtained from the
BALF were counted using a hemocytometer and 4  104 cells were
used to prepare cytospin slides. The cells were stained using the
Quick Panoptic Instant Prov (Newprov) staining Kit, according to
the manufacturer’s instructions, which allows identification of
the different cell types by morphology. The number of neutrophils,
macrophages and lymphocytes were obtained by differential cell
counting of 100 cells through microscopic analysis.
2.5. Recovery of pneumococci from blood and BALF
Individual samples of blood and BALF collected before or at the
indicated time points post infection were diluted serially and pla-
ted onto blood agar. Colony-forming units (CFU) recovered were
counted 18 h after incubation at 37 C in anaerobic jars.
2.6. Antibody and cytokine analysis
The BALF samples were centrifuged at 1000  g for 10 min and
the supernatant stored at 80 C for antibody and cytokine analy-
sis. Antibody production against recombinant PspA and PdT was
evaluated by ELISA using an IgG standard curve and horseradish
peroxidase (HRP) conjugated anti-mouse IgG antibody (Southern
Biotechnology). Cytokine production was directly measured in
the BALF samples. The granulocyte-colony stimulating factor
(G-CSF) and IL-17 were analyzed by ELISA (Peprotec and R&D
System) and IL-2, IL-4, IL-6, IL-10, TNF-a and IFN-c were
determined by Cytometric Bead Array (CBA; BD Bioscience),
according to the manufacturers recommendations.
2.7. Lymphocytes flow cytometry immunophenotyping
BALF samples were collected as described above and 1  106
cells were stained with APC-CY7 conjugated anti-mouse CD3,
PE-CY5 conjugated anti-mouse CD4, PE conjugated anti-mouse
CD8 and FITC conjugated anti-mouse B220 (BD Bioscience). The
flow cytometric acquisition of 30.000 events was performed using
a FACS Canto II (BD, Bioscience) and the data were analyzed using
FlowJo version 7.6.5.
2.8. Antibody binding and complement deposition assays
The ability of antibodies from the BALF of immunized mice
(before challenge) to bind to the PspA exposed on the surface of
the pneumococcal strain WU2 and promote C3 deposition was
evaluated as previously described [10]. Briefly, pneumococci were
incubated with individual and non-diluted BALF samples followed
by incubation with FITC-conjugated anti-mouse IgG antibody
(1:500 in PBS – MP Biomedical) or FITC-conjugated anti-mouse
IgG1 or IgG2 antibody (1:100 in PBS – Southern Biotech). For the
complement deposition assay, after incubation with BALF, pneu-
mococci were washed once with PBS and incubated with 10% nor-
mal mouse sera (NMS) diluted in Hank’s Balanced Salt Solution
(HBSS – GIBCO) containing 0.1% of gelatin (SIGMA). Next, pneumo-
cocci were incubated with FITC-conjugated anti-mouse C3 mole-
cule antibody (1:500 in PBS – MP Biomedical). Samples were
then analyzed by flow cytometry using a FACS Canto II (BD,
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stained pneumococci were used to determine the negative cell
population. The percentage of positive cells was used for statistical
analysis. Additionally, the antibody binding assay was performed
on a parent PspA knock-out strain, JY119, under the same condi-
tions. Geometric mean of fluorescence intensity (Geo MFI) was
evaluated in histograms using the Flow Jo 7.6.5 software.
2.9. Statistical analysis
All results are representative of two independent experiments
(n = 5 per time point for each group). Collected samples were ana-
lyzed individually and shown as means (+SEM). Statistical analyses
were performed by one-way ANOVA with a Tukey’s Multiple Com-
parison Test between the groups using GraphPad Prism: Significant
results are shown by **** p < 0.0001, *** p < 0.001, ** p < 0.01 and
* p < 0.05 versus control group or between groups as indicated by
the connecting bars.3. Results
3.1. rBCG PspA-PdT / rPspA-PdT immunization rapidly controls the
pneumococcal load in the BALF and prevents systemic dissemination
We evaluated the pneumococcal loads recovered from BALF and
blood of mice immunized with rBCG PspA-PdT / rPspA-PdT and
controls in the first hours after an aspiration/intrapulmonary chal-
lenge using the virulent strain, WU2. All immunized groups
showed similar CFU counts (~105–106) in the BALF samples within
the first 6 h post infection, as observed in Fig. 1A. Mice immunized
with WT-BCG or those that received saline (Control) were unable
to limit the infection and the pneumococci counts in the BALF
remained high until the final data point at 72 h (Fig. 1A). In addi-
tion, high pneumococci count (~103–105) was recovered from
blood samples of both groups 24 h post infection (Fig. 1B). BALF
samples from mice immunized with a single dose of rPspA-PdT
showed reduced bacterial count (~104) 12 h post infection
(Fig. 1A), while WT-BCG / rPspA-PdT immunized mice started to
control the infection after 24 h (Fig. 1A). Pneumococci were recov-
ered in the blood samples from these groups 48 h post infection
(Fig. 1 B). On the other hand, mice immunized with rBCG PspA-
PdT / rPspA-PdT started to control the pneumococcal infection at
12 h, showing the lowest bacterial count in the BALF (~102) when
compared with all other groups at this point; the pneumococcal
count continued decreasing and no bacteria was detected 48 h post
infection (Fig. 1A). Furthermore, rBCG PspA-PdT / rPspA-PdT
immunized group did not show pneumococcal dissemination to
the bloodstream (Fig. 1B).
3.2. rBCG PspA-PdT / rPspA-PdT immunization controls the cellular
influx 24 h after the challenge and increases the lymphocytes
recruitment
The cellular influx in the BALF samples was evaluated at the
indicated time-points before or after pneumococcal intranasal
challenge. The total cell count increased in all groups 12 h post
infection (Fig. 2A), which was largely dependent on the increased
neutrophil count at the same time point (Fig. 2B). The increased
neutrophil count remained high in the Control andWT-BCG groups
until the final time-point at 72 h (Fig. 2B). Mice immunized with
WT-BCG / rPspA-PdT or rBCG PspA-PdT / rPspA-PdT started to con-
trol the cellular influx 24 h post infection, showing reduced total
cell and neutrophil counts when compared with control groups
(Fig. 2A and B). Similar results were observed 48 h post infection
in mice that received a single dose of rPspA-PdT (Fig. 2B).Additionally, BALF samples from mice immunized with rBCG
PspA-PdT / rPspA-PdT showed a higher number of lymphocytes
48 h post infection (Fig. 2D) when compared with Control or
WT-BCG groups (Fig. 2D). At the 72-h data point, BALF samples
from mice immunized with rPspA-PdT, WT-BCG / rPspA-PdT or
rBCG PspA-PdT / rPspA-PdT showed reduced total cell counts
(Fig. 2A) and the predominance of macrophages over neutrophils
(Fig. 2C and B). No significant eosinophil counts were observed in
any of the groups tested (data not shown).
3.3. rBCG PspA-PdT / rPspA-PdT immunization controls inflammatory
cytokine production in the BALF
Cytokine production was measured in the BALF samples before
or at the indicated time points post infection. A peak of IL-6 and
G-CSF was observed in all groups at 12 h post infection (Fig. 3A
and B). BALF samples from mice immunized with rPspA-PdT,
WT-BCG / rPspA-PdT or rBCG PspA-PdT / rPspA-PdT showed lower
levels of IL-6 at 48 and 72 h when compared with the Control and
WT-BCG groups (Fig. 3A). In addition, WT-BCG / rPspA-PdT and
rBCG PspA-PdT / rPspA-PdT immunized groups showed reduced
level of G-CSF at 24 h and 48 h (Fig. 3B). TNF-a production was
controlled in BALF samples from mice immunized with rPspA-
PdT, WT-BCG / rPspA-PdT or rBCG PspA-PdT / rPspA-PdT 12 h post
infection (Fig. 3C). In these groups, TNF-a level decreases gradually
and is almost undetectable at the 72-h data point, whereas it
remains higher in the Control and WT-BCG groups (Fig. 3C). While
rPspA-PdT, WT-BCG / rPspA-PdT or rBCG PspA-PdT / rPspA-PdT
groups maintain low levels of IFN-c, this cytokine increases pro-
gressively in samples from the Control group or mice receiving
only WT-BCG (Fig. 3D). No significant differences in IL-10 secretion
were observed, IL-2 and IL-4 were not detected in any of the groups
tested (data not shown).
3.4. rBCG PspA-PdT / rPspA-PdT immunization induces an early CD4+ T
cell response
Since a high lymphocyte count was observed in BALF samples
from mice immunized with rBCG PspA-PdT / rPspA-PdT at 48 h
post infection, we investigated the presence of CD4+, CD8+ or
B220+ cells using flow cytometry. Lymphocyte population was
gated as shown in Supplementary Fig. S1. BALF samples from mice
immunized with rPspA-PdT, WT-BCG / rPspA-PdT or rBCG PspA-
PdT / rPspA-PdT showed increased percentage of CD4+ and CD8+
T cells at 48 h post infection when compared with the Control
group (Fig. 4 A). Interestingly, a higher percentage of CD4+ T cells
was observed in BALF samples from mice immunized with rBCG
PspA-PdT / rPspA-PdT when compared with mice receiving WT-
BCG or a single dose of rPspA-PdT (Fig. 4A). Furthermore, at 72 h
post infection the percentage of CD4+ T cells increased in all groups
that received a dose of recombinant protein (Fig. 4B), while the
percentage of CD8+ T cells and B220+ cells were significantly higher
in samples from mice immunized with rPspA-PdT or rBCG PspA-
PdT / rPspA-PdT (Fig. 4B).
3.5. BALF from mice immunized with rBCG PspA-PdT / rPspA-PdT
showed increased binding of IgG2 and C3 deposition on the
pneumococcal surface
BALF samples were analyzed for the presence of anti-rPspA and
anti-rPdT antibodies by ELISA. The presence of anti-PspA IgG was
observed in BALF from all groups that received a dose of rPspA-
PdT. The group primed with rBCG PspA-PdT and boosted with
rPspA-PdT showed a higher amount of anti-PspA IgG than mice
receiving a single dose of rPspA-PdT (Fig. 5A), no significant levels
of anti-rPdT antibodies were detected in the BALF samples of the
Fig. 1. Immunization of mice with rBCG PspA-PdT / rPspA-PdT controls the pneumococcal loads in the BALF 12 h after the challenge and prevents systemic
dissemination. BALF and blood samples were collected from immunized mice after intranasal challenge with 106 CFU of pneumococcal strain WU2 at the indicated time
points: (A) Pneumococcal count in BALF samples (B) Pneumococcal count in blood samples. Samples were plated on blood agar and the CFU recovered counted after overnight
incubation. Results are representative of two independent experiments (n = 5 per time point for each group) and shown as means (+SEM). Statistical analyses were performed
by one-way ANOVA with a Tukey’s Multiple Comparison Test between the groups using GraphPad Prism: Significant results are shown by *** p < 0.001, ** p < 0.01 and
* p < 0.05 versus the Control group or between groups as indicated by connecting bars.
Fig. 2. rBCG PspA-PdT / rPspA-PdT immunization controls the cellular influx 24 h after the challenge and increases lymphocyte recruitment. BALF samples were
collected from immunized and challenged mice: (A) Number of total infiltrated cells, (B) Neutrophils, (C) Macrophages and (D) Lymphocytes. Total cells were counted using a
hemocytometer. Slides were prepared by cytospin, stained with Instant Prov (Newprov) and 100 cells were differentially counted. Results are representative of two
independent experiments (n = 5 per time point for each group) and shown as means (+SEM). Statistical analyses were performed by one-way ANOVA with a Tukey’s Multiple
Comparison Test between the groups using GraphPad Prism: Significant results are shown by *** p < 0.001, ** p < 0.01 and * p < 0.05 versus the Control group or versus WT-
BCG group as indicated by connecting bars.
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samples were evaluated for their ability to bind to PspA exposed
on the pneumococcal surface. Significantly higher total IgG binding
was observed when the pneumococci were incubated with BALFsamples from mice receiving rBCG PspA-PdT / rPspA-PdT (~67%
of positive cells), followed by rPspA-PdT (~52% of positive cells)
andWT-BCG / rPspA-PdT (~51% of positive cells) (Fig. 5B). Pneumo-
cocci incubated with BALF samples from the Control or WT-BCG
Fig. 3. rBCG PspA-PdT / rPspA-PdT immunization controls cytokines production in the BALF. BALF samples were collected frommice at the indicated time after intranasal
challenge and used for cytokine measurement with Th1/Th2 CBA kit or ELISA: A) IL-6, B) G-CSF, C) TNF-a and D) IFN-c. Results are representative of two independent
experiments (n = 5 per time point for each group) and shown as means (+SEM). Statistical analyses were performed by one-way ANOVA with a Tukey’s Multiple Comparison
Test between the groups using GraphPad Prism: Significant results are shown by *** p < 0.001, ** p < 0.01 and * p < 0.05 versus the Control group or versus WT-BCG group as
indicated by connecting bars.
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addition, high binding of IgG1 (~67% of positive cells) and espe-
cially IgG2c (~48% of positive cells) were observed for BALF sam-
ples from mice immunized with rBCG PspA-PdT / rPspA-PdT
(Fig. 5C and D), whereas samples from mice receiving WT-BCG /
rPspA-PdT or rPspA-PdT showed only binding of IgG1. Likewise,
BALF from rBCG PspA-PdT / rPspA-PdT immunized group promoted
significantly higher C3 deposition (~48% of positive cells) on the
pneumococcal surface than WT-BCG, rPspA-PdT or WT-BCG /
rPspA-PdT groups (~38, 42 and 43% of positive cells, respectively)
(Fig. 5D).
In order to investigate the specificity of binding of the BALF
antibodies to the pneumococcal surface, the same samples were
incubated with a strain of pneumococci lacking PspA. Low anti-
body binding was observed on the surface of JY119, a PspA-
knockout pneumococcal strain when compared to the wild-type
WU2 pneumococcal strain (Fig. 6).4. Discussion
Pneumococcal infections trigger rapid neutrophil recruitment
to the lungs, which can either be essential for bacterial clearance
or lead to an uncontrolled inflammation associated with lung
injury [13]. In this study, a pronounced neutrophil influx was
observed in all groups 12 h post infection. This influx remains high
for the Control and WT-BCG groups, while mice receiving rBCG
PspA-PdT / rPspA-PdT or WT-BCG / rPspA-PdT reduced the cellular
influx 24 h post infection, showing lower airway neutrophilia. The
ability of pneumococcal antigens to induce a controlled inflamma-
tory response in the lungs after infection has been correlated with
effective protection in mice [14–16]. Likewise, an earlier pneumo-
coccal clearance was observed in BALF samples from rBCG PspA-
PdT / rPspA-PdT, WT-BCG / rPspA-PdT and rPspA-PdT immunized
groups, while rBCG PspA-PdT / rPspA-PdT also prevented pneumo-
coccal dissemination to the bloodstream.After the intranasal pneumococcal challenge, IL-6 levels were
increased, peaking at 12 h in all groups, while a decrease was only
observed in rBCG PspA-PdT / rPspA-PdT, WT-BCG / rPspA-PdT and
rPspA-PdT at 24 and 48 h. G-CSF also peaks at 12 h, however
immunization with rBCG PspA-PdT / rPspA-PdT and WT-BCG /
rPspA-PdT reduced the levels of G-CSF 24 h and 48 h post infection.
It has been demonstrated that these cytokines can play an impor-
tant role in the protection at the early stages of pneumococcal
pneumonia [14,16–18]. IL-6 deficient mice showed high pneumo-
coccal loads in the lungs 40 h post infection and died earlier than
wild-type mice [17], while the administration of G-CSF increased
the survival of splenectomized mice after a pneumococcal chal-
lenge by rising the number of circulating neutrophils and improv-
ing lung clearance [19]. On the other hand, the ability to control the
expression of IL-6 and G-CSF after the first 12 h followed by
reduced production of TNF-a and IFN-c during all the infection
can be correlated with protection against tissue damage and
increased survival, as previously demonstrated [14,16].
Mice immunized with rBCG PspA-PdT / rPspA-PdT exhibited a
greater CD4 + T cell recruitment to the lungs 48 h post infection
as compared to mice that received a single dose of rPspA-PdT. Sim-
ilar percentages of CD4+, CD8+ and B220+ were observed between
rBCG PspA-PdT / rPspA-PdT and rPspA-PdT groups only after
72 h. The role of T and B lymphocytes in the prevention of pneumo-
coccal lung infection and sepsis are still unclear. CD4+ T cells
expressing IL-17 were described as essential to protect against
pneumococcal colonization [21], while CD8-/- mice were shown
to be more susceptible to serotype 3 pneumococcal infection
[22]. However, the depletion of CD4+, CD8+ T cells or B lympho-
cytes did not abrogate the protection induced by mice immunized
with PspA [14].
We have previously demonstrated that the s.c. immunization of
mice with WT-BCG / rPspA-PdT or rBCG PspA-PdT / rPspA-PdT
induced a higher IgG antibody response in the serum than a single
dose of rPspA [11], while only the rBCG PspA-PdT / rPspA-PdT
immunization promoted IgG class switching from IgG1 to IgG2c.
Fig. 4. rBCG PspA-PdT / rPspA-PdT immunization induces an early CD4+ T cell response. BALF samples were collected from mice at (A) 48 h or (B) 72 h after intranasal
challenge and stained with APC-CY7 conjugated anti-mouse CD3, PE-CY5 conjugated anti-mouse CD4, PE conjugated anti-mouse CD8 or FITC conjugated anti-mouse B220.
Flow cytometry analysis was performed using FACS Canto II and 30,000 gated events were recorded; data was analyzed using FlowJo. Results are representative of two
independent experiments (n = 5 per time point for each group) and shown as means (+SEM). Statistical analyses were performed by one-way ANOVA with a Tukey’s Multiple
Comparison Test between the groups using GraphPad Prism: Significant results are shown by *** p < 0.001, ** p < 0.01 and * p < 0.05 versus the Control group or between
groups as indicated by connecting bars.
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effective immune response in the lungs, characterized by the high
antibody response in the BALF. Immunization with rBCG PspA-PdT
/ rPspA-PdT induced higher anti-PspA IgG levels in the BALF than a
single dose of rPspA-PdT. Furthermore, whereas all tested groups
promoted high binding of IgG1 to the pneumococcal surface, only
BALF from mice receiving rBCG PspA-PdT / rPspA-PdT showed
binding of IgG2c antibody to the pneumococci and promoted high
complement deposition. The IgG antibody binding was specific to
the PspA molecule, since no binding was observed in a PspA-KO
strain of pneumococci. The IgG2 isotype has been described to effi-
ciently bind to the pneumococcal surface, enhancing complement
deposition and phagocytosis [11,14,23]. We have previously
shown that rBCG PspA-PdT / rPspA-PdT immunization induced
increased production of IFN-c before challenge, which is required
for production of IgG2c [11]. Here we show the reduction in
IFN-c after challenge, at a timepoint where IgG2c has already beenproduced. While the production of IFN-c by T cells is required to
promote antibody isotype switching to IgG2c [20] as observed after
immunization of mice with rBCG PspA-PdT / PspA-PdT [11], the
control of IFN-c secretion in the lungs after pneumococcal chal-
lenge has been shown to be important for a favorable prognostic
[14,16].
Priming with either WT-BCG or rBCG PspA-PdT induced similar
humoral and cellular immune responses after the booster dose
with rPspA-PdT. This phenomenon is due to a non-specific effect
of BCG, which has been termed ‘‘trained immunity” [24]. This
‘‘trained immune” response induced by WT-BCG immunization is
relatively short-lived and does not induce a memory response, as
we have demonstrated by the reduced expression of the CD69
molecule on splenic CD4+ T cells of WT-BCG / rPspA immunized
mice [11]. Furthermore, we did not detect anti-PdT antibodies in
the BALF, perhaps reflecting the lower immunogenicity of this anti-
gen in comparison to PspA, or dilution of the antibodies in the total
Fig. 5. BALF from mice immunized with rBCG PspA-PdT / rPspA-PdT showed increased IgG2 binding and C3 deposition on the pneumococcal surface. BALF samples
were collected from mice before the pneumococcal challenge. (A) The anti-PspA antibody production was evaluated by ELISA. Pneumococcal WU2 strain was incubated with
BALF samples from mice immunized with WT-BCG, rPspA-PdT, WT-BCG /rPspA-PdT, rBCG PspA-PdT / rPspA-PdT or the Control group, followed by incubation with FITC
conjugated mouse antibodies (B) IgG, (C) IgG1, (D) IgG2 or (E) C3. For the C3 deposition assay, 10% of NMS was added. Flow cytometry analysis was conducted using FACS
Canto II and 20,000 gated events were recorded and the data analyzed using FlowJo version 7.6.5. Non-stained pneumococci sample was used to determine the negative cell
population. Results are representative of two independent experiments (n = 5 per time point for each group) and shown as means (+SEM). Statistical analyses were performed
by one-way ANOVA with a Tukey’s Multiple Comparison Test between the groups using GraphPad Prism: Significant results are shown by **** p < 0.0001, *** p < 0.001, **
p < 0.01 and * p < 0.05 versus the Control group or between groups as indicated by connecting bars.
C. Goulart et al. / Vaccine: X 4 (2020) 100049 7volume of BALF samples. Indeed, we have previously demonstrated
that immunization with rBCG PspA-PdT / rPspA-PdT induces an
antibody response in the serum able to inhibit the hemolytic activ-
ity of Ply in red blood cells [11], suggesting an important role of
anti-PdT antibodies in the protection against systemic infection.
Similarly, the production of IgA against PspA and PdT was only
detected in the antisera of immunized mice (data not shown).
Wilson, et al., demonstrated that naturally acquired protective
immunity to pneumococcal lung infection requires both humoral
and cell-mediated immune responses [25]. In fact, using the rBCG
PspA-PdT with a booster dose of rPspA-PdT we observed the pres-
ence of high antibody levels in the lungs followed by a controlled
cellular influx with increased lymphocyte recruitment. Taken
together, our results suggest that immunization with rBCG PspA-
PdT prime/ rPspA-PdT boost induces humoral and cellular immune
responses in the lungs, and the early clearance of pneumococci inthe BALF protects against the systemic dissemination of the pneu-
mococcal disease.CRediT authorship contribution statement
Cibelly Goulart: Conceptualization, Formal analysis, Investiga-
tion, Methodology, Writing - original draft, Writing - review & edit-
ing. Dunia Rodriguez: Conceptualization, Formal analysis,
Investigation, Methodology, Writing - review & editing. Alex I.
Kanno: Formal analysis, Investigation, Methodology, Writing -
review & editing. José Lourenço S.C. Silva: Formal analysis, Inves-
tigation, Methodology. Luciana C.C. Leite: Conceptualization,
Formal analysis, Funding acquisition, Investigation, Project admin-
istration, Resources, Supervision, Writing - original draft, Writing -
review & editing.
Fig. 6. IgG antibodies induced by immunization with rBCG PspA-PdT / rPspA-PdT bind onto the surface of PspA+ but not PspA- pneumocococal strain. Pneumococci
were incubated with non-diluted BALF samples followed by incubation with FITC-conjugated anti-mouse IgG antibody (1:500 in PBS – MP Biomedical). Samples were then
analyzed by flow cytometry using a FACS Canto II (BD, Bioscience). Geometric mean of fluorescence intensity (Geo MFI) was evaluated in histograms using the Flow Jo 7.6.5
software. Results are representative of two independent experiments using pooled BALF samples.
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